New Report by BioTrends Research Group to Highlight the Launch of SIMPONI(R) (golimumab)

EXTON, Pa., April 27 /PRNewswire/ -- BioTrends is pleased to announce the fielding of a new syndicated report, LaunchTrends(TM): SIMPONI(R). Cenotcor Ortho Biotech, Inc. announced that they received FDA approval for SIMPONI(R) (generic name: golimumab) on April 24, 2009. The first once-monthly subcutaneous anti-TNF-alpha therapy, SIMPONI is approved for the treatment of moderately to severely active rheumatoid arthritis, active psoriatic arthritis, and active ankylosing spondylitis. The product will be available in two dosing delivery forms: the SIMPONI SmartJect autoinjector and a prefilled syringe.

LaunchTrends: SIMPONI is a four wave primary market research study that consists of a quantitative on-line survey and qualitative telephone interviews. In total, 300 Rheumatologists will participate in the research. Following a baseline report, three additional waves will be published capturing launch effectiveness at one month, three months, and six months post launch. The reports are designed to assess trial and use of SIMPONI(R), obstacles to use, typical patient types, product perceptions, promotional efforts/messages, and satisfaction with the product relative to other agents.

About BioTrends Research Group, Inc. BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com. All company, brand, or product names contained in this document may be trademarks of their respective holders.

SOURCE BioTrends Research Group, Inc.